214 related articles for article (PubMed ID: 8982281)
1. Effect of introduction of an arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors.
Gourlet P; Vandermeers A; Vandermeers-Piret MC; De Neef P; Waelbroeck M; Robberecht P
Biochim Biophys Acta; 1996 Dec; 1314(3):267-73. PubMed ID: 8982281
[TBL] [Abstract][Full Text] [Related]
2. Interaction of amino acid residues at positions 8-15 of secretin with the N-terminal domain of the secretin receptor.
Gourlet P; Vilardaga JP; De Neef P; Vandermeers A; Waelbroeck M; Bollen A; Robberecht P
Eur J Biochem; 1996 Jul; 239(2):349-55. PubMed ID: 8706739
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
Simonneaux V; Kienlen-Campard P; Loeffler JP; Basille M; Gonzalez BJ; Vaudry H; Robberecht P; Pévet P
Neuroscience; 1998 Aug; 85(3):887-96. PubMed ID: 9639281
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes.
Gourlet P; Vandermeers-Piret MC; Rathé J; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
Eur J Pharmacol; 1998 May; 348(1):95-9. PubMed ID: 9650836
[TBL] [Abstract][Full Text] [Related]
5. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Gourlet P; Vandermeers A; Van Rampelbergh J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Ann N Y Acad Sci; 1998 Dec; 865():247-52. PubMed ID: 9928018
[TBL] [Abstract][Full Text] [Related]
6. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
[TBL] [Abstract][Full Text] [Related]
7. The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors.
Gourlet P; Vilardaga JP; De Neef P; Waelbroeck M; Vandermeers A; Robberecht P
Peptides; 1996; 17(5):825-9. PubMed ID: 8844773
[TBL] [Abstract][Full Text] [Related]
8. Construction of chimeras between human VIP1 and secretin receptors: identification of receptor domains involved in selectivity towards VIP, secretin, and PACAP.
Du K; Nicole P; Couvineau A; Laburthe M
Ann N Y Acad Sci; 1998 Dec; 865():386-9. PubMed ID: 9928035
[No Abstract] [Full Text] [Related]
9. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
Gourlet P; Rathé J; De Neef P; Cnudde J; Vandermeers-Piret MC; Waelbroeck M; Robberecht P
Eur J Pharmacol; 1998 Jul; 354(1):105-11. PubMed ID: 9726637
[TBL] [Abstract][Full Text] [Related]
10. The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins.
Van Rampelbergh J; Poloczek P; Françoys I; Delporte C; Winand J; Robberecht P; Waelbroeck M
Biochim Biophys Acta; 1997 Jun; 1357(2):249-55. PubMed ID: 9223629
[TBL] [Abstract][Full Text] [Related]
11. Properties of chimeric secretin and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination.
Vilardaga JP; De Neef P; Di Paolo E; Bollen A; Waelbroeck M; Robberecht P
Biochem Biophys Res Commun; 1995 Jun; 211(3):885-91. PubMed ID: 7598719
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation.
Hashimoto H; Ogawa N; Hagihara N; Yamamoto K; Imanishi K; Nogi H; Nishino A; Fujita T; Matsuda T; Nagata S; Baba A
Mol Pharmacol; 1997 Jul; 52(1):128-35. PubMed ID: 9224822
[TBL] [Abstract][Full Text] [Related]
13. Retinoic acid regulation of the VIP and PACAP autocrine ligand and receptor system in human neuroblastoma cell lines.
Waschek JA; Lelievre V; Bravo DT; Nguyen T; Muller JM
Peptides; 1997; 18(6):835-41. PubMed ID: 9285932
[TBL] [Abstract][Full Text] [Related]
14. C-terminally shortened pituitary adenylate cyclase-activating peptides (PACAP) discriminate PACAP I, PACAP II-VIP1 and PACAP II-VIP2 recombinant receptors.
Gourlet P; Vandermeers A; Vandermeers-Piret MC; Rathé J; De Neef P; Robberecht P
Regul Pept; 1996 Apr; 62(2-3):125-30. PubMed ID: 8795075
[TBL] [Abstract][Full Text] [Related]
15. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
16. Development of high affinity selective VIP1 receptor agonists.
Gourlet P; Vandermeers A; Vertongen P; Rathe J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Peptides; 1997; 18(10):1539-45. PubMed ID: 9437714
[TBL] [Abstract][Full Text] [Related]
17. Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin receptors for recognition of the ligand's third residue.
Perret J; Van Craenenbroeck M; Langer I; Vertongen P; Gregoire F; Robberecht P; Waelbroeck M
Biochem J; 2002 Mar; 362(Pt 2):389-94. PubMed ID: 11853547
[TBL] [Abstract][Full Text] [Related]
18. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
19. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes.
Jiang X; Wang HY; Yu J; Ganea D
Ann N Y Acad Sci; 1998 Dec; 865():397-407. PubMed ID: 9928038
[TBL] [Abstract][Full Text] [Related]
20. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
